Gentler dose tested to control prostate cancer before surgery
NCT ID NCT04530552
Summary
This study is testing if a very low dose of the drug apalutamide can help control prostate cancer before surgery. It involves men whose cancer is still confined to the prostate gland. The main goal is to see if this short, low-dose treatment can effectively lower PSA levels, a key marker of cancer activity.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
George Washington University Medical Center
Washington D.C., District of Columbia, 20037, United States
-
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland, 21287, United States
-
NCI - Center for Cancer Research
Bethesda, Maryland, 20892, United States
-
USC / Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
-
University of Arizona Cancer Center - Prevention Research Clinic
Tucson, Arizona, 85719, United States
Conditions
Explore the condition pages connected to this study.